Skip to main content

Scribe Therapeutics, Inc.

SCTX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001853921

No open-market purchases or sales by Scribe Therapeutics, Inc. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q3 2026, worth $297.1M in total; ARK Invest is the only superinvestor holding it.

Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Nov 13, 2026, 1:22 AM ET

No financial statements

Scribe Therapeutics, Inc. has no annual statements on file yet. See the quarterly statements.